Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials

Abstract

Background: Previous phase 3 trials showed significant bronchodilation in patients (pts) with COPD in response to once-daily REV. Aims & Objectives: We evaluated whether REV 175 µg improved health status and dyspnea in pts with moderate to severe COPD irrespective of baseline symptom status. Methods: Data from 12-week (0126/0127) and 52-week (0128) trials were analyzed. Health status was measured with the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), and St George’s Respiratory Questionnaire (SGRQ), and dyspnea with the modified Medical Research Council dyspnea scale. The impact of baseline symptom status (Table) on response to therapy was assessed. At Day 85 (0126/0127) and Day 92 (0128), REV was compared with control therapies (placebo [PBO, 0126/0127]; tiotropium [TIO, 0128]). Results: Overall, REV showed greater improvements vs PBO/TIO in health status and dyspnea, irrespective of baseline symptom status, with significant improvements in CAT, CCQ, and SGRQ in pts with uncontrolled symptoms in 0126/0127 (Table). A trend toward a larger treatment response was observed in pts with uncontrolled symptoms; this is likely due to these pts having a greater opportunity to improve. Conclusions: Improvements in health status and dyspnea occurred in REV-treated pts regardless of baseline symptomatic measure.